Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector

Journal of Immunology

Volumn 162, Issue 3, 1999, Pages 1603-1610

  Fennelly, Glenn J ^a   Khan, Shibber A ^a   Abadi, Maria A ^a   Fabian Wild, T ^b   Bloom, Barry R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CONCANAVALIN A; DNA VACCINE; GAMMA INTERFERON; MEASLES VACCINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TOLERABILITY; IMMUNE RESPONSE; INTRANASAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOCYTE ACTIVATION; MEASLES; MEASLES VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHIGELLA FLEXNERI; TREATMENT OUTCOME;

EID: 0033082546     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Centers for Disease Control. 1997. Progress toward global measles control and elimination, 1990-1996. Morbid. Mortal. Wkly. Rep. 46:893.
2. Murray, C. J. L., and A. D. Lopez. 1996. How the world dies today. In The Global Burden of Disease: a Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020 - Summary, C. J. L. Murray and A. D. Lopez, eds. World Health Organization, Geneva, Switzerland, p. 14.
3. Halsey, N. A. 1993. Increased mortality after high titer measles vaccines: too much of a good thing. Pediatr. Infect. Dis. J. 12:462.
4. Sizemore, D. R., A. A. Branstrom, and J. C. Sadoff. 1995. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 270:299.
5. Arya, S. C. 1994. Human immunization in developing countries: practical and theoretical problems and prospects. Vaccine 12:1423.
6. Leon, M. E., B. Ward, R. Kanashiro, H. Hemandez, S. Berry, A. Vaisberg, J. Escamilla, M. Campos, S. Bellomo, V. Azabache, et al. 1993. Immunologic parameters 2 years after high-titer measles immunization in Peruvian children. J. Infect. Dis. 168:1097.
7. Centers for Disease Control. 1996. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection. 1993. Morbid. Mortal. Wkly. Rep. 45:603.
8. Miller, C. 1987. Live measles vaccine: a 21-year follow-up. Br. Med. J. 295:22.
9. Good, R. A., and S. J. Zak. 1956. Disturbances in gammaglobulin synthesis as "experiments of nature." Pediatrics 18:109.
10. Lipsey, A. I., M. J. Kahn, and R. P. Bolance. 1967. Pathologic variants of congenital hypogamma-globulinemia: an analysis of 3 patients dying of measles. Pediatrics 39:659.
11. + T cells are essential in overcoming experimental murine measles encephalitis. Immunology 83:184.
12. Mills, J. A., J. M. Buysse, and E. V. Oaks. 1988. Shigella flexneri invasion plasmid antigens B and C: epitope location and characterization with monoclonal antibodies. Infect. Immun. 56:2933.
13. Manthorpe, M., F. Cornefert-Jensen, J. Hartikka, J. Felgner, A. Rundell, M. Margalith, and V. Dwarki. 1993. Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Hum. Gene Ther. 4:419.
14. Mallett, C. P., L. VanDe Verg, H. H. Collins, and T. L. Hale. 1993. Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model. Vaccine 11:190.
15. Birrer, M. J., B. R. Bloom, and S. Udem. 1981. Characterization of measles polypeptides by monoclonal antibodies. Virology 108:381.
16. Gilman, R. H., R. B. Hornick, and W. E. Woddard. 1977. Evaluation of UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a live oral vaccine. J. Infect. Dis. 136:717.
17. Beauverger, P., R. Buckland, and T. F. Wild. 1993. Establishment and characterization of murine cells constitutively expressing the fusion, nucleoprotein and matrix proteins of measles virus. J. Virol. Methods 44:199.
18. Spehner, D., A. Kirn, and R. Drillien. 1991. Assembly of nucleocapsid like structures in animals cells infected with a vaccinia virus recombinant encoding the measles virus nucleoprotein. J. Virol. 65:2696.
19. Oglesbee, M. 1992. Intranuclear inclusions in paramyxovirus-induced encephalitis: evidence for altered nuclear body differentiation. Acta Neuropathol. 84:407.
20. Way, S. S., A. C. Borezuk, R. Dominitz, and M. B. Goldberg. 1998. An essential role for interferon-γ in innate resistance to Shigella flexneri infection. Infect. Immun. 66:1342.
21. Van de Verg, L. L., C. P. Mallet, H. H. Collins, T. Larsen, C. Hammack, and T. L. Hale. 1995. Antibody and cytokine responses in a mouse pulmonary mode! of Shigella flexneri serotype 2a infection. Infect Immun. 63:1947.
22. Finke, D., U. G. Brinckmann, V. ter Meulen, and U. G. Liebert. 1995 Gamma interferon is a major mediator of antiviral defense in experimental measles virus-induced encephalitis. J. Virol. 69:5469.
23. Griffin, D. E., and B. J. Ward 1993. Differential CD4 T cell activation in measles. J. Infect. Dis 168:274.
24. von Herrath, M. G., M. Yokama, J. Dockter, M. B. Oldstone, and J. L. Whittle. 1996. CD-4 deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J. Virol. 70:1072.
25. Malvoisin E., and F. Wild. 1990. Contribution of measles virus fusion protein in protective immunity: anti-F monoclonal antibodies neutralize virus infectivity and protect mice against challenge. J. Virol. 64:5160.
26. Giraudon, P., and T. F. Wild. 1985. Correlation between epilopes on hemagglutinin of measles virus and biological activities: passive protection by monoclonal antibodies is related to their hemagglutinalion inhibiting activity. Virology 144:46.
27. Krugman, S. 1963. Medical progress in the use of gamma globulin. N. Engl. J. Med. 269:195.
28. Chen, R. T., L. E. Markowitz, P. Albrecht, J. A. Stewart, L. M. Mofenson, S. R. Preblud, and W. A. Orenstein. 1990. Measles antibody: revaluation of protective titers. J. Infect. Dis. 162:1036.
29. van Binnendijk, R. S., M. C. M. Poelen, G. van Amerongen, P. de Vries, and A. D. M. E. Osterhaus. 1997. Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J. Infect. Dis. 175:524.
30. Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145.
31. Formal, S. B., T. L. Hale, and C. Kapfer. 1989. Shigella vaccines. Rev. Infect. Dis. 11:S547.
32. Black, R. E., M. M. Levine, M. L. Clements, G. Losonsky, D. Herington, S. Berman, and S. B. Formal. 1987. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J. Infect. Dis. 155:1260.
33. Cohen, D., M. S. Green, C. Block, T. Rouach, and I. Ofek. 1988. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J. Infect. Dis. 157:1068.
34. Mallett, C. P., L. VanDeVerg, H. H. Collins, and T. L. Hale. 1993. Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model. Vaccine 11:290.
35. Mathan, M. M., and V. I. Mathan. 1991. Ultrastructural pathology of the rectal mucosa in Shigella dysentery. Rev. Infect. Dis. 13:S314.
36. Levine, M. M., C. Ferreccio, S. Cryz, and E. Ortiz. 1990. Comparison of entericcoated capsules and liquid formulation of Ty21 a typhoid vaccine in randomized controlled field trial. Lancet 336:891.
37. Langermann, S., S. Palaszynski, A. Sadziene, C. K. Stover, and S. Koenig. 1994. Systemic and mucosa! immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature 372:552.
38. Noriega, F. R., G. Losonsky, J. Y. Wang, S. B. Formal, and M. M. Levine. 1996. Further characterization of ΔaroA ΔvirG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenie Escherichia coli. Infect. Immun. 62:23.
39. Gallichan, W. S., and K. L. Rosenthal. 1996. Long-lived T lymphocytes memory in mucosal tissues after mucosal but not systemic immunization. J. Exp. Med. 184:1879.
40. Mallett, C. P., L. Van De Verg, H. H. Collins, and T. L. Hale. 1993. Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model. Vaccine 11:290.
41. Steger, K. K., and C. D. Pauza. 1997. Immunization of Macacu mulatta with aroA attenuated Salmonella typhimuriun expressing the SIVp27 antigen. J. Med. Primatol. 26:44.
42. Zhu, Y., G. Fennelly, C. Miller, R. Tarrara, I. Saxe, B. R. Bloom, and M. McChesney. 1997. Recombinant Bacille Calmette-Guérin expressing the measles virus nucleoprotein protects infant rhesus macaques from measles virus pneumonia. J. Inject. Dis. 176:1445.
43. Ikonomidis G., D. A. Portnoy, W. Gerhard, and Y. Paterson. 1997. Influenza-specific immunity induced by recombinant Listeria monocytogenes vaccines. Vaccine 15:433.
44. Fennelly, G. J., J. L. Flynn, V. ter Meulen, U. G. Liebert, and B. R. Bloom. 1995. Recombinant Bacille Calmette-Guérin priming against measles. J. Infect. Dis. 172:698.
45. Hess, J., I. Gentschev, D. Miko, M. Welzel, C. Ladel, W. Goebel, and S. H. Kaufman. 1996. Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Proc. Natl. Acad. Sci. USA 93:1458.
46. Shen, H., J. F. Miller, X. Fan, D. Kolwyck, R. Ahmed, and J. T. Harty. 1998. Compartmentalization of bacterial antigens: differential effects on priming of CD8 T cells and protective immunity. Cell 92:535.
47. Darji, A., C. D. Guzman, B. Gerstel, P. Wachholz, K. N. Timmis, J. Wehland, T. Chakraborty, and S. Weiss. 1997. Oral somatic transgene vaccination using S. typhimurium. Cell 91:765.
48. Eriksson, K., E. Ahlfors, A. George Chandy, D. Kaiserlain, and C. Czerkinsky. 1996. Antigen presentation in the murine oral epithelium. Immunology 88:147.
49. Liu, L. M., and G. G. McPherson. 1993. Antigen acquisition by dendritic cells: intestinal dendritic cells acquire antigen administered orally and can prime native T cells in vivo. J. Exp. Med. 177:1299.
50. Courvalin, P., S. Goussard, and C. Grillot-Courvalin. 1995. Gene transfer from bacteria to mammalian cells. C. R Acad. Sci. 318:1207.
51. Sansonetti, P. J., J. Arondel, A. Fontaine, H. d'Hauteville, and M. L. Bernardini. 1991. OmpB(osmo-regulation) and icsA (cell to cell spread) mutants of Shigella flexneri vaccine candidates and probes to study the pathogenesis of shigellosis. Vaccine 9:416.
52. Salyers, A. A. and D. D. Whitt. 1994. Dysentery caused by Shigella species. In Bacterial pathogenesis: a molecular approach. A. A. Salyers and D. D. Whitt, eds. American Society for Microbiology, Washington, DC, p. 174.
53. Giannasca, P. J., J. A. Boden, and T. P. Monath. 1997. Targeted delivery of antigen to hamster nasal lymphoid lymphoid tissue with M-cell-directed lectins. Infect. Immun. 65:4288.
54. Kuper, C. F., P. J. Koornstra, D. M. Hameleers, J. Biewenga, B. J. Spit, A. M. Duijvestijn, P. J. van Breda Vriesman, and T. Sminia. 1991. The role of nasopharyngeal lymphoid tissue. Immunol. Today 13:219.
55. Cardoso, A. I., N. Sixt, A. Vallier, J. Fayolle, R. Buckland, and T. F. Wild. 1998. Measles virus DNA vaccination: antibody isotype is determined by the method of immunization and by the nature of both the antigen and the co-immunized antigen. J. Virol. 72:2516.
56. Benson, D. A., M. S. Boguski, D. J. Lipman, J. Ostell, and B. F. F. Ouellette. 1998. GenBank. Nucleic Acids Res. 26:1.
57. Roman, M., E. Martin-Orozco, J. S. Goodman, M. D. Nguyen, Y. Sato, A. Ronaghy, R. S. Kornbluth, D. D. Richman, D. A. Carson, and E. Raz. 1997. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3:849.
58. Ulmer, J. B., J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. L. Felgner, V. J. Dwarki, S. H. Gromkowki, R. Randall Deck, C. M. DeWitt, A. Friedman, et al. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745.
59. Epstein, S. L., C-Y. Lo, J. A. Misplon, and J. R. Bennink. 1998. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J. Immunol. 160:322.